Protein A-Sepharose Chromatography. 2 ml of ascites fluid was processed on a 7-ml protein ASepharose (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) column (11) . Antibody binding to HTLV was assayed on 1 : 1,000 dilutions of eluted fractions by the solidphase RIA (7) .
Radioimmune Precipitation (RIP) . Approximately 150,000 cpm ofiodinated HTLVcR proteins (7) in 50 pl RIP buffer containing 50 mM sodium phosphate, pH 8.0, 0.3 M NaCI, 10% glycerol, 0.2% Triton X-100, 0.1% gelatin, 0.02% NAN3, and 0.5 mM phenyl methyl sulfonyl fluoride (PMSF) were incubated 4-6 h at 4°C with 50 ~1 of a 1:5,000 dilution of ascites fluid. 250/~1 of a 10% (vol/vol) suspension of protein A-Sepharose in RIP buffer was added. Samples were incubated overnight with mixing and were centrifuged. Pellets were washed with 1 ml RIP buffer. Immune precipitates were boiled in Laemmli sample buffer (12) and subsequently electrophoresed on 12% polyacrylamide gels.
Affinity Chromatography. Hybridoma 12/1-2 IgG1, purified on protein A-Sepharose, was coupled to CNBr-Sepharose 4B (Pharmacia Fine Chemicals). 12SI-HTLVcR proteins in phosphate-buffered saline (PBS) were applied to the column and eluted with 0.2 M glycine-HC1, pH 2.8. The 2-ml fractions were neutralized with I00 #1 2 M Tris-HC1, pH 8.0. The unbound and bound proteins were pooled separately, dialyzed against 10 mM NH4HCOz, lyophilized, and dissolved in 10 mM sodium phosphate buffer, pH 8. 100-#1 portions of each fraction were electrophoresed on 12% polyacrylamide gels (12) that were subsequently sliced and counted. Molt
Indirect Immune Fluorescence Assay. Cells (3 × 106) were washed with PBS and suspended in 200 #1 of a 1:15 dilution of PBS. Aliquots (1-2/~1) were spotted on slides, air dried, and fixed for 10 min at room temperature in 50% methanol:50% acetone. Slides were stored at -20°C until use. Ascites of hybridoma 12/1-2 or control ascites of P3x63 cells, diluted 1:400 in PBS, was applied to cells and incubated 30 min. The fluorescein-conjugated F(ab')2 fragment of sheep anti-mouse IgG (N. L. Cappel Laboratories Inc., Cochranville, Pa.) was purified through a human IgG-Sepharose column, diluted, and applied to cells. After 30 rain incubation at room temperature, slides were washed for 1-2 h in PBS before microscopic examination.
Cells. The isolation of HTLVeR from HUT102 cells derived from a patient (C.R.) with CTCL has been described (1), as have CTCL-3 cells derived from a second blood sample of patient C.R. (1). CR-CTC cells were derived independently from a third blood sample of patient C.R. by Dr. T. Waldmann. Dr. M. Maeda cloned the HUT102 cells. CTCL-2 cells derived from cells of a patient with cutaneous T cell leukemia were the source of the second HTLV isolate, strain MB (2). Other patient lymphocytes were examined either as fresh or fresh-frozen cells, or else were examined after culture in the presence of T cell growth factor (TCGF) (13) . Normal peripheral blood lymphocytes were cultured using phytohemagglutinin and TCGF (13) . Virus-infected cells included human B cells infected with but not producing woolly monkey (simian sarcoma associated) virus (LBv20B/SSAV); gibbon ape leukemia virus (LBv20A/GaLV) (14) ; human lymphoblasts infected with simian sarcoma virus (NC37/SSV); bat lung cells infected with baboon endogenous virus (88/M28); feline embryo fibroblasts infected with strain A, B, or C of feline leukemia virus (FEA/FeLVA, FEA/FeLVB, FEA/ FeLVC); bat lung cells infected with GaLV, Thai strain (88/GaLVThai); mouse fibroblasts Results and Discussion Of several monoclonal antibodies to HTLV, one produced by hybridoma 12/1-2 has been especially useful. Ouchterlony analysis and metabolic labeling indicated that this hybridoma synthesizes IgG1 with a kappa light chain ( Fig. 1 a and b) . A confirmation of this subtype and evidence that binding of 12/I-2 ascites fluid to HTLV was antibody mediated was obtained by coincident elution of antibody and binding activity from a protein A-Sepharose column at pH 6 (11; Fig. 1 c) . An RIP assay for HTLV proteins illustrated the specificity of the antibody. Among the iodinated HTLV proteins (Fig. 2 a) only p 19 could be specifically precipitated (Fig.  2 b) . (The molecular weight of p19 varies with measurement from 16,000 to 19,000.) Hybridoma 12/1-2 IgGrSepharose also specifically bound the p19 protein (Fig. 2c,  d , and e). The column used was too small to quantitatively bind all the p19 (Fig. 2c  and d) . However, reapplication of the first eluate to the column resulted in specific binding of HTLV p19 (Fig. I e) .
In indirect immune fluorescent assays this anti-pl9 specifically labels only HTLVproducing cells (Table I) . Transformed HUT78 cells, also derived from a patient with CTCL, do not produce HTLV and are negative for p 19. The percentage of fluorescent ceils in a positive sample varies. Both HUT102 parental cells and clones are 60-70% positive, suggesting that viral expression might be related to cell cycling. CTCL-2 and CTCL-3 ceils are 5 and 12% positive, respectively. Presumably, not all the cells are producing virus. Alternatively, some cells might express virus at levels too low to detect by this assay. In fact, CTCL-2 cells require iododeoxyuridine (IdU) induction for significant virus production (2) . Normal peripheral blood lymphocytes and human T and B cell lines examined were all negative for the presence of HTLV p19 (Table  I) , emphasizing the viral specificity of the antibody. Anti-pl9 does not recognize cells producing other mammalian RNA tumor viruses, which further substantiates the lack of relationship of HTLV to these viruses.
The fluorescent labeling of virus-positive cells is restricted to the cell membrane (Fig. 3) . Only fixed cells can be labeled, supporting the notion that p19 is an internal HTLV protein (4) and not an envelope component. Whereas conventional antisera to an internal viral protein might stain the cytoplasm of virus-producing ceils, the monoclonal antibody only recognizes p19 when the virus is assembled at the cell membrane.
TCGF has enabled growth of malignant mature T cells, resulting in isolation of HTLV (1, 2) . Two of the HTLV-producing cell lines, HUT102 and CTCL-2 cells, now grow independently of exogenous factor. Presumably, TCGF caused stimulation of virus production by expansion of the appropriate cell population. We have looked for expression of HTLV p 19 in cells of other patients with CTCL as well as of patients with other leukemias. Both fresh and cultured cells have been examined. So far, all attempts to detect HTLV in this fashion have been negative, including those in which we tried to induce HTLV production using IdU (Table II) . It is clear that HTLV p19 is not expressed in most malignant T cells, indicating that replicating HTLV is not present. Whether HTLV is present more commonly but is not completely expressed, is present only in the early stages of disease, or is present in only a subset of T cell leukemias is not known. The monoclonal antibody to HTLV p19 provides an assay for HTLV expression for determining the frequency of HTLV replication in human T cells and for studying the regulation of viral gene expression. Summary A monoclonal antibody specific for the internal p 19 protein of a type-C retrovirus (HTLV) isolated from human neoplastic T cells has been developed. Its specificity has been shown by radioimmune precipitation and by affinity chromatography of iodinated HTLV proteins. By indirect immune fluorescence this antibody recognizes only HTLV-producing cells. Examination of cells from patients with cutaneous T cell lymphomas and leukemias and with other types of lymphomas and leukemias indicated that HTLV p 19 expression is rare. The monoclonal antibody will be useful in determining the natural reservoir of HTLV, possibly in a subset of mature T cell neoplasias.
